Considering that IL-1β is one of the signaling pathways of rheumatoid arthritis and periodontitis, a therapeutic option is the use of an IL-1 receptor antagonist (IL-1RA) that prevents IL-1β signaling. This evidence concerns the gene IL1B and periodontitis.